- Avivagen (VIV) has announced significant new and expanded sales of the company’s companion animal products
- The new sales include a 1,500-unit order for Vivamune from an existing distribution partner in Taiwan, as well as two new customer wins in Mexico
- Avivagen has also announced the departure of Chris Boland as Chief Financial Officer
- Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications
- Avivagen Inc. opened trading at C$0.18 per share
Avivagen (VIV) has announced significant new and expanded sales of the company’s companion animal products.
The new sales include a 1,500-unit order for Vivamune from an existing distribution partner in Taiwan, and two new customer wins in Mexico.
The company explains that the 1,500-unit order represents the largest single order from Avivagen’s Taiwan-based distribution partner this year and reflects increased consumer awareness and interest for Vivamune in Taiwan.
OxC-beta complex is also a key ingredient by a leading producer of premium dog food in Taiwan. The company recently expanded its product line of dog food containing OxC-beta to include canned food in addition to its dry kibble product.
In addition, the first of two new customers in Mexico, an independent distributor of high-quality nutritional products for dogs, has ordered 4,000 white labelled products, which it will market under its brand.
The second Mexican customer has placed an initial order for 500 units of Vivamune, which follows its own successful internal study and which it plans to market through veterinary clinics and hospitals.
“We are seeing great interest and opportunity for Avivagen in the companion animal market today,” noted Kym Anthony, Chief Executive Officer of Avivagen.
“These new sales and customer wins in key markets like Taiwan and Mexico follow sales in Canada and the U.S., and are clear signs of the growing demand for our companion animal product as an important part of promoting pet health,” he added.
Furthermore, Avivagen has announced the departure of Chris Boland as Chief Financial Officer. The company expects to announce a new leader for its financial functions soon.
Avivagen is a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that promote general health and performance by safely supporting immune function.
Avivagen Inc. opened trading at C$0.18 per share.
